NICE Draft Guidance: Osimertinib Excluded for Maintenance Treatment of Certain NSCLC Cases
BTOG shared on X:
“BTOG can confirm that NICE has released draft guidance as follows:
Osimertinib should not be used for the maintenance treatment of locally advanced (stage 3) unresectable non-small cell lung cancer (NSCLC) in adults when the tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and the cancer has not progressed during or after platinum-based chemoradiotherapy.
This recommendation is not intended to affect treatment with osimertinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.
Click for full details on the NICE website.”
Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared BTOG’s post:
“So NICE is not So ‘NICE’ to
‘Laura’. To be fair , Laura was much better conducted trial (as compared to ADAURA) and this decision probably has more to do with economics (of the country) than Science alone. What do u think?”
More posts featuring BTOG.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023